Relieves osteoarthritis and rheumatoid arthritis. ANDA 78420, held by Sciegen Pharms. Nabumetone.
As of Nov 15, 2026, ANDA 78420 (Nabumetone), held by Sciegen Pharms, was first approved by FDA on Sep 24, 2008, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets, USP and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets, USP are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2008 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nov 21, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 24, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters